

Special Issue

Marine Toxins in Non-traditional Vectors

Message from the Guest Editors

Marine biotoxins are produced naturally by certain species of algae and bacteria in a wide range of aquatic environments and can accumulate in marine invertebrates. Historically, the primary focus has been upon the presence of toxins in bivalve mollusc shellfish. More evidence is building, however, for the uptake of marine toxins into non-bivalve molluscs, such as gastropods. Other marine phyla have also been associated with biotoxin presence, including echinoderms, arthropods, cnidarians, bryazoa and annelids, nematodes and flatworms. Furthermore, there are also reports of shellfish toxins being associated with uptake into fish, impacting animal health. This Special Issue aims to focus on the interactions of non-bivalve marine organisms with harmful blooms of algae or bacteria and the consequent accumulation of biotoxins in their tissues. There is a growing need to focus not only on the presence of toxins in a wide range of pelagic and benthic organisms, but to also assess the impacts these processes may have on human food safety, animal health and ecosystem status (e.g., a One Health perspective). This Special Issue is dedicated to the memory of Dr Ann Abraham, USFDA.

Guest Editors

Dr. Andrew Turner

Centre for Environment, Fisheries and Aquaculture Science, Weymouth Laboratory, Lowestoft, UK

Dr. Tim Harwood

Cawthron Institute, Nelson, New Zealand

Deadline for manuscript submissions

closed (30 June 2022)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/61886

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))